ASH: Argenx cues up a second use for efgartigimod
pharmaphorum
DECEMBER 12, 2022
of the Vyvgart arm and 20% of the placebo group met the criteria for response to ITP, which include a reduction in bleeding episodes in addition to improvements in platelet counts. After 24 weeks, 21.8% All told, 51.2%
Let's personalize your content